"Quad" Drug

See also: HIV Drugs in Development

Studies on Pipeline ARVs: Quad, Evitegravir/Cobicistat, Cobicistat, GSK1265744, BMS986001 Dolutegravir, GSK-1265744, Long-Acting Formulations (Monthly Injections): Rilpivirine-LA, Raltegravir and Patient Views (May/June 2012)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
U.S. FDA Panel Recommends Gilead's Quad for HIV (May 14, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Quad Fixed-Dose Integrase Combination: Phase 3 Studies at Week 48 (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
CROI 2012: New Full-Regimen Quad Pill as Effective as Atripla (March 26, 2012)
From Project Inform
On TheBodyPRO.com
May 11 FDA Advisory Committee Meeting: Fixed-Dose Combination Tablet of Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate (March 26, 2012)
From U.S. Food and Drug Administration
CROI 2012 Really Rapid Review -- With CROI 2013 Dates! (March 15, 2012)
From Journal Watch
Gilead Quad HIV Drug Causes Fewer Side Effects (March 9, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
Data Show Gilead's Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study (March 8, 2012)
From Gilead Sciences, Inc.
On TheBodyPRO.com
Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study (March 7, 2012)
Quad currently under review for marketing approval by U.S. and European regulatory agencies.
From Gilead Sciences, Inc.
On TheBodyPRO.com
The "Quad" (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Gilead and J&J Expand HIV Cocktail Partnership (November 16, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Gilead: Second Trial of 4-Drug AIDS Pill Meets Goal (September 20, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Lofty Hopes Confront Gilead's Four-Drug HIV Pill (September 12, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Gilead Says 4-in-1 HIV Pill Met Goal in Study (August 16, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Cobicistat Has Little Impact on CYP2D6 and CYP2B6 (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Elvitegravir/Cobicistat and Acid Reducing Agents (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Quad Reduces Levels of Oral Contraceptives (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
"Quad Pill" Continues to Do Well in Early Study (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
Attention: QUAD Is in the Building (December 8, 2010)
Part of "Top HIV/AIDS-Related Clinical Developments of 2010," by David Wohl, M.D.
From TheBody.com
"Quad" Pill Continues to Impress in Week-48 Results; Cobicistat Moves Forward in Battle With Ritonavir (September 14, 2010)
In The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
Four-in-One HIV Pill Enters Late-Stage Clinical Testing (April 13, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
The Debut of the Quad Pill (March/April 2010)
In Treatment Update, from Canadian AIDS Treatment Information Exchange
"Quad" Tablet vs. Atripla; GS 9350 (Cobicistat) vs. Ritonavir (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Good Results for New Booster and Quad Pill (Winter/Spring 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
The Once and Future King: What Will Replace Atripla Atop the First-Line HIV Treatment Realm? (Feb. 19, 2010; 3:39 p.m. Pacific Time)
A blog entry from CROI 2010 by Gerald Pierone Jr., M.D.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
QUAD Four-in-One Pill as Strong as Atripla, but a Kidney Concern Arises (February 18, 2010)
From National AIDS Treatment Advocacy Project
Elvitegravir "Quad" Pill Performs Well, New Booster Cobicistat Works as Well as Ritonavir (February 18, 2010)
From aidsmap.com
The New Quad on the Block: Gilead's Four-Drug, Fixed-Dose Combination With a Novel Booster Sails Through Phase 2 Trials (Feb. 18, 2010; 1:15 a.m. Pacific Time)
A blog entry from CROI 2010 by Myles Helfand.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Four-Drug Combination Has High Success Rate in HIVers With Multidrug Resistance (October 19, 2009)
From aidsmap.com
Gilead Aiming to Put Four HIV Drugs in One Pill (January 14, 2009)
From aidsmap.com
Step Aside, Atripla? New Four-in-One Pill to Enter Development (January 12, 2009)
From Bloomberg.com